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Introduction: Patients with Chronic Obstructive Pulmonary Disease (COPD) have been shown to
experience significant pain that interferes with their daily activities and quality of life. The
purpose of this study was to examine if pain is associated with functional exercise capacity (as-
sessed with the six-minute walk test, 6MWT), physical activity (assessed by accelerometry),
and muscle performance (maximal knee extensor torque) in people with COPD.
Methods: Twenty-six people with moderate to severe COPD completed the McGill Pain Question-
naire (MPQ), the Brief Pain Inventory (BPI), the Short Form-36 (SF-36), anda form to listmedications
and comorbidities. After spirometric testing, participants performed the 6MWT. Physical activity
wasmonitored for twodaysusing a tri-axial accelerometer (DynaPortMiniMod). At least 3 days after
the 6MWT, maximal and fatiguing concentric contractions of knee extensors were assessed.
Results: Pain severity was negatively correlated with the 6MWT (p < 0.05), and quality of life
(p < 0.05), whereas it was positively correlated with body mass index (BMI) (p < 0.001), and the
number of comorbidities (p< 0.001). Subjectswith severe pain showed lower standing and activity
times (p< 0.01), lower 6MWT (p< 0.05), higher BMI (p< 0.001), a higher number of comorbidities
(p < 0.001) and lower quality of life (p < 0.01) compared to subjects with minimal or no pain.
Conclusion: Pain inpatientswithCOPD is associatedwith lowfunctionalexercise capacity, reduced
physical activity, and high BMI. Pain can adversely affect physical activity and quality of life inhysics Laboratory, Rm 600 e 828 West 10th Avenue, Vancouver, BC V6T 1M9, Canada. Tel.: þ1 604 875
ni.ubc.ca, baharehg@interchange.ubc.ca (B. HajGhanbari).
Copyright ª 2013 Published by Elsevier Ltd. All rights reserved.
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Pain and physical performance in COPD 1693patients with COPD. Early evaluation of pain needs to be considered in the assessment and treat-
ment plan for people with COPD.
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People with stable COPD experience significant pain
compared to age- and gender-matched healthy people and
pain interferes with their daily activities [1e3]. COPD pa-
tients demonstrated 2.6 times more pain and 3.7 times
more pain interference with daily activities compared to an
age- and a gender-matched healthy cohort [1]. This greater
prevalence of pain in COPD patients is similar to two other
recent studies. Bensten et al. demonstrated that a signifi-
cantly higher percentage of patients with COPD (45%) re-
ported pain than the control group (34%; p Z 0.02) [2].
Borge et al. stated that 72% of the patients with COPD re-
ported pain as assessed by a body diagram [3]. These in-
vestigations unequivocally indicate that pain in COPD
patients is more common and more severe compared to
healthy people. Further investigation is required to better
understand the impact of pain on physical activities.
Fatigue, dyspnea [4,5], and muscle weakness [6,7] are
commonly reported to adversely affect functional mobility
and physical capacity in COPD patients. Pain is another
factor that may contribute to limitations of physical ac-
tivity in this chronic respiratory disease similar to how pain
affects people with other disorders. Physical activity is
limited in those with osteoarthritis [8], and it is associated
with reduced health related quality of life (HRQoL) in pa-
tients with nonmalignant pain [9]. In spite of the apparent
frequent occurrence of this symptom, the effects of pain on
muscle performance in people with COPD has not been
described. A better understanding of how pain in COPD
affects physical performance would facilitate the design of
more effective prescription of exercise, physical activities,
and help maintain independent mobility.
In order to provide further insight into the experience of
pain in COPD and whether pain can be considered as an
additional activity-limiting factor in COPD (besides fatigue
and dyspnea), we determined the relationships between
pain and three physical performance measures: 1) muscle
performance (concentric torque of knee extensors), 2)
physical activity levels (as measured by triaxial accel-
erometry), and 3) six minute walk test (6MWT).Methods and materials
Subjects
A convenience sample of 26 people with moderate to se-
vere COPD (forced expiratory volume in one second [FEV1]
of 30%  FEV1 < 80% predicted, FEV1/FVC <0.7) [10] were
recruited from rehabilitation programs at local hospitals
and from the local respirologists. People with COPD were
included if they: 1) had moderate to severe disease [10];
and 2) were over 50 years of age. Participants wereexcluded if they: 1) had experienced an acute exacerbation
of COPD during the last 3 months; 2) had unstable cardio-
vascular, neurological, musculoskeletal or other condi-
tion(s) that interfere with independent ambulation or safe
performance of the testing; 3) had taken oral corticoste-
roids within the last three months; 4) had cognitive
impairment; and 5) were not fluent in English. The clinical
ethics board at the University of British Columbia approved
the study and all subjects gave informed written consent
before participation in the study.
Protocol
Participants were asked to refrain from physical exercise,
caffeine and alcohol on test days. Participants made two
visits to the laboratory. During the first laboratory visit,
spirometry was performed to determine disease severity
and patients were asked to fill out questionnaires including:
a form to list medications and co-morbidities, the Medical
Outcomes Study Short Form-36 (SF-36), the short form of
McGill Pain Questionnaire (MPQ), the short form of the Brief
Pain Inventory (BPI), and a form for screening the risks of
exercise based on American College of Sports Medicine
(ACSM) guidelines. Height and weight were measured, and
each subject performed the 6MWT. Subjects were famil-
iarized with the accelerometer, and received instructions
on how to wear and use the device supplemented with a
manual containing written instructions and figures. Sub-
jects were asked to wear the device for two full days.
During the second laboratory visit (at least 3 days after the
first visit), subjects were tested for maximal voluntary
concentric torque of the knee extensors, followed by re-
petitive fatiguing maximal concentric contractions using an
isokinetic Biodex dynamometer. Medication history and in-
formation about comorbidities were confirmed by chart
review.
Outcomes and measurements
Spirometry was performed to determine COPD severity
from FEV1 and FVC values and percent-predicted values
were calculated using prediction equations derived from
the third National Health and Nutrition Examination Survey
(NHANES III) [11].
Pain severity was assessed using the MPQ and BPI. The
MPQ consists of: 1) fifteen items to assess sensory compo-
nents; 2) four items to assess affective aspects of pain over
one week; 3) a visual analogue scale to provide the in-
tensity score of the pain over one week; and 4) a Present
Pain Intensity (PPI) scale. This form is reported to be reli-
able [12], valid [13], and has been found to be appropriate
for use with geriatric patients who experience pain [14].
The BPI was used to identify pain locations on a body
diagram and to assess two dimensions of pain: severity and
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measures the interference of pain in the seven aspects of a
patient’s life including: general activity, mood, walking,
sleep, normal work, enjoyment of life, and relationship
with others. The BPI has been shown to have predictive
validity in a number of patient populations with chronic
conditions [15,16]. Because of differing attributes, both the
BPI and MPQ were used to provide a more comprehensive
description of the pain experienced by individuals [17]. The
MPQ has been shown to be an excellent tool to evaluate the
quality of pain while the BPI is preferred in the assessment
of physical function and functional impact of pain [18]. MPQ
and BPI scores were calculated as the percentage of the
maximum score that could be obtained on each component
of the questionnaire: severity for MPQ and BPI, and inter-
ference for BPI.
Assessment of functional exercise capacity was performed
using the 6MWT [19]. Briefly, participants were instructed to
walk as far as they could in 6 min in a 30-m loop located in a
hallway,andthetotaldistancewalkedwas recorded inmeters.
Percent predicted values for 6MWTwere calculated based on
themethod described by Enright & Sherrill [20]. Assessment of
HRQoL was performed using SF-36 [21].
Assessment of physical activity level in daily life (activity
monitoring) was performed with a DynaPort MiniMod Move-
Monitor (McRoberts, The Hague, The Netherlands). The de-
vice has been validated and used in people with COPD. It
measures step counts, and the time spent in different pos-
tures, such as standing, sitting or lying, walking and loco-
motion. Data were processed through online software to
estimate physical activity for 2 days [22,23]. Subjects were
asked to wear the accelerometer for 2 full days between the
two laboratory visits. The data were assessed from 9 am to
9 pm on each day for the purpose of the analysis [23]. Par-
ticipants were asked to perform their usual daily activities
and not to change their routine while wearing the device
[22]. For the purpose of data analysis, total number of step
counts over 2 days, and the activity durations (inminutes) for
different types of activity (lying, sitting, walking, and
standing) were recorded.
Maximal voluntary concentric torque of the knee ex-
tensors was assessed on the dominant leg (the leg that a
person uses to kick a ball) using an isokinetic dynamometer
(Biodex System 4; Biodex, Shirley, NY). The shin pad was
placed at 75% of the distance from the head of the fibula to
the distal edge of the lateral malleolus. The knee was
aligned with the rotating lever. Subjects were familiarized
with producing maximal concentric contractions of the
knee extensors. Concentric torque of the knee extensor
muscles was tested by having the subject performing 3 to 5
sub-maximal warm-up contractions followed by 5 maximal
voluntary contractions (MVC) through a range of motion
from 80 to 10 of knee flexion at an angular velocity of 90
per second [24]. Participants received vigorous verbal
encouragement. MVCs were performed until the maximum
force recorded during two contractions differed by 5% or
less [25]. The highest MVC peak torque was used to repre-
sent the subject’s maximal concentric contraction [25].
For the fatigue protocol, subjects performed repetitive
maximal concentric contractions of the knee extensors
while the counter movements were performed passively by
the device. The contracting and passive return time ratiowas 2:1 with a 1 s rest during the counter movement. Sub-
jects were asked to perform as many contractions as they
could up to a maximum of 100 contractions [24]. Visual and
verbal feedback was provided during each contraction to
ensure that the maximum amount of force was produced.
The first 34 contractions were chosen for measuring fatigue
index (FI) because it was the maximum number of contrac-
tions that all patients were able to perform. The FI was
calculated by the following formula to yield a percentage
decrease in peak isokinetic torque: FIZ 100  [(Peak MVC of
34th contractionO Peak MVC of 1st contraction)  100] [26].
Statistical analysis
Statistical analyses were performed using the SPSS software
package (version 16.0, Chicago, IL). Frequencies were
determined for the total number of pain locations, comor-
bidities and medications. Descriptive statistics were per-
formed to describe subject characteristics and frequency
distributions of the outcomes. The distribution of data was
tested for normality using the KolmogoroveSmirnov and
ShapiroeWilk tests. Levene’s test was used to test for the
homogeneity of the variances. Pain severity, as measured by
MPQ and BPI, was tested for correlations with the physical
activity data (step counts, activity duration), peak torque,
fatigue index (FI), and HRQoL (SF-36). The Pearson product
moment correlation coefficient (PCC) was used for normally
distributed data and the Spearman’s correlation coefficient
was used for non-normally distributed data. Correlations (r)
were categorized as low (0 < r < 0.25), moderate
(0.25 < r < 0.50), strong (0.50 < r < 0.75), and very strong
(0.75 < r) [27].
The subjects were divided into two groups: those with
severe pain and those with mild to moderate or no pain,
and two-tailed t-tests were performed to investigate be-
tween group differences in functional exercise capacity,
physical activity, muscle performance, and HRQoL. The cut
points of 30, 40, and 40% were selected for MPQ intensity,
BPI severity and BPI interference scores, respectively,
based on visual inspection of the distribution plots. The
ratio of the number of patients with mild to moderate pain
for MPQ, BPI severity, and BPI interference scores were
(21/5), (20/6), and (21/5), respectively. The significance
level of p < 0.05 was selected.
Results
Twenty-six patients with moderate to severe COPD
completed the study. Subjects had a mean age of 70.4  9.3
years (14 males), and a mean BMI within the normal range
(Table 1). Means and standard errors for pain levels, 6MWT,
quality of life scores; physical activity and torque measures
are reported in Table 2.
MPQ pain severity was negatively correlated with the
6MWT (Table 3, Fig. 1). Subjects with severe pain (based in
the MPQ) walked a shorter total distance (115  57 m;
p < 0.01) (Table 4). Females walked 350  121 m (70%
predicted) while males walked 402  119 m (88% predicted).
Those with more pain had 41% less active time (p < 0.01),
had 49% less standing time (p < 0.01), and had 16% more
sedentary time (p < 0.05) (Table 4). No significant







Age (years) 72.6  10.6 67.8  6.9 70.4  9.3
BMI (kg/m2) 26.5  4.4 26.8  6.3 26.4  5.3
FEV1 (% predicted) 48.4  15.4 47.7  17.0 48.9  15.8
FEV1/FVC 0.61  0.16 0.59  0.17 0.60  0.16
BMI: body mass index; FEV1: Forced expiratory volume in one
second; FVC: forced vital capacity.
Table 3 Significant correlations between pain measures
and 6MWT, quality of life measures, number of comorbid-
ities, and BMI (p < 0.05).
Variable MPQ BPI-S BPI-I
6MWT % predicted 0.41
SF-36 PCS 0.43 0.39 0.40
SF-36 MCS 0.40 0.59*
Number of comorbidities 0.70* 0.42 0.47
BMI 0.47* 0.50*
The table shows the r value for Spearman or Pearson correla-
tions; all comparisons are significant at p < 0.05 except for the
values with asterisks that are significant at p < 0.001.
Abbreviations: MPQ: McGill Pain Questionnaire; BPI-S: BPI
severity score; BPI-I: BPI interference score; 6MWT: Six minute
walk distance test; PCC: SF-36 Physical Component Score; MCS:
SF-36 Mental Component Score; BMI: body mass index.
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pain severity or pain interference.
MPQ pain severity, BPI pain severity, and BPI interfer-
ence scores were negatively correlated with the Physical
Component Score (PCS) of SF-36 (p < 0.05) (Table 3). Be-
tween group comparisons showed that those subjects with
more pain severity (p < 0.01) and interference (p < 0.001)
scored lower on PCS of the SF-36 (Table 4). Significant
negative correlations were found between Mental Compo-
nent Score (MCS), and pain severity (p < 0.05) and pain
interference (p < 0.001) of the BPI (Table 3). Between
group comparisons also showed that those with more severe
pain (BPI) and greater pain interference (on the BPI) had
lower MCS of the SF-36 (p < 0.05).
MPQ severity (p < 0.001, Fig. 1) and BPI interference
scores (p < 0.05) were positively correlated with BMI (Table
3). Compared to those with minimal or no pain, subjects
with severe pain reported more pain interference with dailyTable 2 Pain, functional exercise capacity, physical ac-
tivity, health-related quality of life and muscle perfor-
mance measures (mean  SE).
Category Variable Mean  SE
Pain severity MPQ 16.8  3.1
BPI-S 27.3  5.0




6MWT % predicted 82.7  4.8
HRQoL SF-36 PCS 35.7  1.9
SF-36 MCS 48.3  3.0
Physical activity Step count 4588  548
Standing time (min) 146.4  12.9
Sedentary time (min) 486.7  15.9
Active time (min) 219.9  16.8
Muscle
performance
Fatigue index 52.1  2.7
CON Tmax (N m) 90.5  7.0
MPQ: McGill Pain Questionnaire; BPI-S: BPI severity score; BPI-I:
BPI interference score; 6MWT: Six minute walk test; HRQoL:
health related quality of life; PCS: SF-36 Physical Component
Score; MCS: SF-36 Mental Component Score; CON Tmax: Peak
concentric torque.activities as measured on the BPI (p < 0.05), and had on
average 2e3 more comorbidities (Table 4). The number of
comorbidities was positively correlated with MPQ severity
(p < 0.001) (Table 3, Fig. 1), BPI severity, and interference
scores (p < 0.05) (Table 3). The most common comorbid
condition was cardiovascular (54%), followed by endocrine
that included osteoporosis (50%), and musculoskeletal dis-
ease (46%). Of the 26 patients, eight had diagnosed osteo-
porosis, 11 had diagnosed osteoarthritis, and 9 reported
calf pain during the 6MWT.
Subjects with more pain had a higher number of pain
locations and medications (Table 4). Consistent with the
fact that all subjects had a diagnosis of COPD and the most
prevalent comorbidity was cardiovascular disease (nZ 14),
respiratory and cardiac medications were the most common
(n Z 70).Discussion
Our study demonstrated that pain severity (assessed by the
MPQ) was inversely related to 6MWT. People with more
severe pain walked 25.6% less than those with moderate to
no pain on the 6MWT. Those with severe pain also had
significantly lower standing and activity times, and a higher
sedentary time as compared to those with less pain. BMI
and the number of comorbidities were positively associated
with pain severity and those with severe pain had 2 to 3
more comorbidities compared to those with lower levels of
pain.
During the 6MWT, those with more pain walked 114 m
less than those with less or no pain. Based on the normative
values described by Bohannon [28], our male participants
walked 53 m, and females walked149 m less than their age
and gender predicted distances. These differences are
considerably higher than the minimal important difference
of 25 m for the 6MWT in people with COPD [29]. Limitations
of the 6MWT have been attributed to COPD-related symp-
toms and comorbidities [30]. Painful osteoarthritis (OA) of
the hips or knees might be another underlying cause of
limited walk distance in addition to symptoms of fatigue
and dyspnea; 42% (11 of 26) of our COPD participants had
Figure 1 Significant correlations between pain severity
measured on the McGill Pain Questionnaire (MPQ) vs the 6
minute walk test (6MWT) (r Z 0.41, p < 0.005), body mass
index (BMI) (rZ 0.70, p < 0.001), and number of comorbidities
(r Z 0.47, p < 0.001).
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with aging from 14% at the age of 50 to 58% at the age of 86
years [31]. OA most commonly affects the hips, knees
and hands [32] and might contribute to pain and limited
walk distance in people with COPD. Another potential
cause of pain during walking might be the intermittent
claudication of the calf muscles associated with the high
prevalence of cardiovascular diseases in COPD. Thirty-five
percent (9 of 26) of our sample reported calf pain during
the 6MWT.
Lower levels of physical activity were demonstrated in
COPD patients who experience pain, as shown by shorter
standing and active time, and sedentary time being
approximately twice the active time. Similar mean differ-
ences in sitting, standing and active times have been re-
ported when COPD patients were compared to healthy age-
and gender-matched controls [24]. Lower physical activity
levels could be, in part, due to osteoporosis and OA that
were reported by the significant proportion of our patients
(31% and 42%, respectively). Osteoporosis [33e35] and
associated spinal compression fractures are more common
in people with COPD (31% of patients vs 18% of controls)
[36]. Pain due to osteoporosis-related vertebral fractures is
significant as shown by ratings of 6e7 out of 10 cm on a
visual analogue scale [37,38]. The contribution of
osteoporosis-related compression fractures to pain and
physical inactivity in people with COPD requires further
study. Another reason might be the pain associated with
OA. Similar to COPD, physical inactivity is very common in
people with OA [39,40] and has been shown to be associ-
ated with severe pain in people with OA [41]. Thus, it is
likely that OA of lower extremities and back may have
contributed to decreased standing and active time in COPD
patients with severe pain.
Other pain-inducing activity limiting factors in COPD
patients might be related to the specific medications and
symptoms of deconditioning i.e. calf pain that was reported
in 35% of our patients. It has been documented that some
COPD specific medications, such as beta-2 agonists cause
cramps in the calf muscles [42] that might interfere with
walking ability and activity duration in COPD patients.
Furthermore, decreased physical activity and its related
deconditioning effects in COPD [43] might contribute to the
increased pain in COPD over time. According to the Vlaey-
en’s fear-avoidance model [44], the vicious cycle of
deconditioning begins with an attempt to avoid pain by
reducing daily physical activities. While avoiding activity
may result in less pain over the short term, the reduction in
activity may lead to more deconditioning, which then can
lead to increased pain in some disorders. The increase in
pain then leads to more avoidance of activity.
We found a significant positive correlation between BMI
andMPQpain severity and BPI interference in COPDpatients.
This is consistent with data from a recent study that found a
higher BMI in people with COPD who experienced more pain
as compared to those with no pain [3]. Chronic pain is re-
ported to be strongly associated with obesity in the elderly
[45]. Obesity (as measured by BMI) is known to be an im-
portant health issue in patients with COPD with a reported
prevalence that ranges from 28% [46] to 54% [47]. Obesity
is postulated to increase the prevalence of pain by in-
creasing proinflammatory cytokines, and increasing the risk
Table 4 Significant between group differences for 6MWT, physical activity measures, BMI, number of comorbidities, pain
locations and medications, and quality of life measures.
Outcomes MPQ BPI severity BPI interference
6MWT (% predicted) 25.6  11.3** 10.9  11.4 19.1  11.8
Sedentary time (min) 56.4  40.9* 89.9  36.7* 39.3  41.2
Standing time (min) 4.4  33.5 78.3  19.2** 7.9  33.5
Active time (min) 4.8  40.5 99.1  35.3** 19.3  43.3
BMI (kg/m2) 3.1  2.6 4.3  2.4 5.7  2.4*
Number of comorbidities 3.0  0.6y 2.0  1.5** 2.2  0.7y
Number of pain locations 6.0  1.3y 3.6  1.5** 3.5  1.6*
Number of medications 3.3  1.9* 2.1  1.8 4.1  1.8*
SF-36 PCS 11.9  4.3** 4.7  4.6 13.2  4.2y
SF-36 MCS 6.8  7.7 14.7  6.6* 20.4  6.6y
Groups were defined as those with severe pain vs those with minimal to moderate pain based on the maximum scores achieved on MPQ
and BPI severity, and BPI interference measures. Data are mean  SE. * significance level of p < 0.05, ** significance level of p < 0.01, y
significance level of p < 0.001.
Abbreviations: MPQ: McGill Pain Questionnaire; BPI: Brief Pain Inventory; BMI: body mass index; 6MWT: Six minute walk distance test;
PCC: SF-36 Physical Component Score; MCS: SF-36 Mental Component Score.
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pain might also increase the risk of obesity by reductions in
physical activity or hormonal changes [45].
There was evidence of knee extensor muscle weakness
and fatigability in our subjects with an average peak tor-
que of 90.5 N m for the whole group compared to previ-
ously reported values of 203 and 179 N m for healthy males
and women, respectively [24]. Furthermore, the average
torque reduction was 50% with only 34 repetitions which is
consistent with another report of COPD patients [24].
Despite this clear deterioration in muscle performance, we
did not find significant correlations between maximal
concentric torque and pain severity in patients with COPD.
This is similar to the findings of Steultjens et al. who found
no clear relationship between pain and muscle strength in
123 patients with hip and knee OA and that muscle strength
only accounted for about 5% of the variance in pain levels
[49]. Given that muscle weakness has been well docu-
mented in COPD, one explanation for the lack of associa-
tion with pain could be that other factors such as the
systemic effects of the disease account for the major loss
of muscle strength in COPD. These systemic effects include
the prolonged inflammation, and changes in muscle
metabolism and structure (fiber atrophy, fiber loss).
Another reason might be related to the small sample size
and variability amongst subjects in muscle strength, and
fatiguability may have resulted in type II error. Further-
more, we found that the fatigue index was not related to
pain severity. This finding suggests that the distance trav-
eled in the 6MWT might be influenced more by pain, pul-
monary and cardiovascular factors than muscle fatigue of
the knee extensors.Limitations
The major limitation of this study was the relatively small
sample size, especially when the group was divided in two
groups. We used convenience sampling such that our sam-
ple was recruited from a small geographical location, whichmight limit the generalizability of our findings. However, it
is unlikely that our subjects were different in any system-
atic way from the usual COPD patients attending these
clinics. The study did not consider the social and psycho-
logical aspects of pain as a multidimensional experience
that might affect how each patient responds to various
items in the questionnaires that queried pain. Finally,
muscle testing was limited to the knee extensors.
Conclusion
Our study demonstrated that pain in people with COPD is
associated with decreased exercise capacity and physical
activity, and higher BMI. The implications of these findings
are that the evaluation of pain should be considered in the
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